دورية أكاديمية
أعرض في EDS

Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018

التفاصيل البيبلوغرافية
العنوان: Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018
المؤلفون: Coenen S, van der Velden AW, Cianci D, Goossens H, Bongard E, Saville BR, Gobat N, de Paor M, Ieven M, Verheij TJ, Butler CC
بيانات النشر: Royal College of General Practitioners
سنة النشر: 2020
المجموعة: McMaster University: MacSphere
مصطلحات موضوعية: COVID-19, Europe, coronavirus, oseltamivir, primary care, randomised controlled trial, Adolescent, Adult, Aged, Antiviral Agents, Child, Coronavirus Infections, Drug Therapy, Combination, Female, Fever, Headache, Humans, Influenza, Human, Male, Middle Aged, Pandemics, Pneumonia, Viral, Time Factors, Treatment Outcome, Young Adult
الوصف: BackgroundPatients infected with the novel coronavirus (SARS-CoV-2) are being treated empirically with oseltamivir, but there is little evidence from randomised controlled trials to support the treatment of coronavirus infections with oseltamivir.AimTo determine whether adding oseltamivir to usual care reduces time to recovery in symptomatic patients who have tested positive for coronavirus (not including SARS-CoV-2).Design and settingExploratory analysis of data from an open-label, pragmatic, randomised controlled trial during three influenza seasons, from 2016 to 2018, in primary care research networks, in 15 European countries.MethodPatients aged ≥1 year presenting to primary care with influenza-like illness (ILI), and who tested positive for coronavirus (not including SARS-CoV-2), were randomised to usual care or usual care plus oseltamivir. The primary outcome was time to recovery defined as a return to usual activities, with minor or absent fever, headache, and muscle ache.ResultsCoronaviruses (CoV-229E, CoV-OC43, CoV-KU1 and CoV-NL63) were identified in 308 (9%) out of 3266 randomised participants in the trial; 153 of these were allocated to usual care and 155 to usual care plus oseltamivir; the primary outcome was ascertained in 136 and 147 participants, respectively. The median time to recovery was shorter in patients randomised to oseltamivir: 4 days (interquartile range [IQR] 3–6) versus 5 days (IQR 3–8; hazard ratio 1.31; 95% confidence interval = 1.03 to 1.66; P = ...
نوع الوثيقة: article in journal/newspaper
اللغة: unknown
تدمد: 0960-1643
1478-5242
العلاقة: http://hdl.handle.net/11375/26508Test; https://doi.org/10.3399/bjgp20x711941Test
DOI: 10.3399/bjgp20x711941
الإتاحة: https://doi.org/10.3399/bjgp20x711941Test
http://hdl.handle.net/11375/26508Test
حقوق: Attribution - CC BY This Creative Commons license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. Recommended for maximum dissemination and use of licensed materials. ; 2 ; Attribution - CC BY
رقم الانضمام: edsbas.F4B50935
قاعدة البيانات: BASE
الوصف
تدمد:09601643
14785242
DOI:10.3399/bjgp20x711941